Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: Onyvax-P, Onyvax.

Christian Doehn1, Torsten Böhmer, Dieter Jocham

  • 1University of Lübeck Medical School, Department of Urology, Lübeck, Germany. doehn@medinf.mu-luebeck.de

Current Opinion in Molecular Therapeutics
|October 27, 2005
PubMed
Summary

Onyvax-P is an allogeneic whole-cell vaccine being developed for prostate cancer treatment. This novel therapy is currently progressing through phase II clinical trials to evaluate its efficacy and safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Current Data from the National Registry for Urothelial Cancer (UroNAT) by d-uo].

Aktuelle Urologie·2026
Same author

[7-Year Data on Penile Carcinoma from the VERSUS Study by d-uo].

Aktuelle Urologie·2026
Same author

[Early Detection of Prostate Cancer: Current Real-World Data from the VERSUS Study by d-uo].

Aktuelle Urologie·2026
Same author

[Current Data from the National Registry for Prostate Cancer (ProNAT) by d-uo].

Aktuelle Urologie·2026
Same author

[Healthcare Research in Renal Cell Cancer: 7-Year-Data from the VERSUS Study by d-uo].

Aktuelle Urologie·2026
Same author

First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

Cancers·2025

Area of Science:

  • Oncology
  • Immunotherapy
  • Vaccinology

Background:

  • Prostate cancer remains a significant global health challenge.
  • Current treatment options for advanced prostate cancer have limitations.
  • There is a need for novel therapeutic strategies, including cancer vaccines.

Purpose of the Study:

  • To evaluate the safety and efficacy of Onyvax-P, an allogeneic whole-cell vaccine, for prostate cancer treatment.
  • To assess the potential of Onyvax-P as a novel immunotherapy approach.

Main Methods:

  • Onyvax-P is an allogeneic whole-cell vaccine.
  • The vaccine is derived from non-human cells.
  • Clinical trials are being conducted to assess its therapeutic potential.

Main Results:

  • The abstract does not contain specific results as the vaccine is in phase II clinical trials.
  • Further data will be generated from ongoing clinical studies.

Conclusions:

  • Onyvax-P represents a promising investigational therapy for prostate cancer.
  • Phase II clinical trials are crucial for determining the vaccine's clinical utility.

Related Experiment Videos